The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not. A randomized trial compared TDM to no TDM in patients receiving infliximab for chronic immune-mediated inflammatory diseases (IMIDs) and found that TDM did not increase the odds of achieving remission.
Dr. John Cush RheumNow
5 years 5 months ago
Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w
Dr. John Cush RheumNow
5 years 5 months ago
TNF inhibitor induced (paradoxical) psoriasis in JIA patients was 3 fold higher when TNFi was used - data from 8,222 children in the CARRA registry (54% used TNFi) - rate 8.5 cases/1000PY. https://t.co/HKpAEbtNqr https://t.co/txvmGfpdWf
Dr Ai Lyn Tan DrAiLynTan
5 years 5 months ago
27 cases of #immune-mediated diseases post #COVIDVaccination
▶️21 had autoimmune/rheumatic background
▶️17 flares, 10 new onset
▶️Average 4 days post #covidvaccine
▶️>80% had resolution, mostly with corticosteroid
👉🏽https://t.co/zHlFziswU7
via @Vaccines_MDPI @MDPIOpenAccess https://t.co/5ifoBmb9Ux
Laurent ARNAUD Lupusreference
5 years 5 months ago
#VACOLUP study about #COVID19 #vaccine in #lupus = reassuring data for #SLE patients : side-effects are minor/moderate in 80% and the rate of lupus #flare is stable at 3-4%. Thanks to the 571 patients who have already participated 🙏.
Link: https://t.co/I0D52fv4BC https://t.co/us0kQlvkVS
Dr. John Cush RheumNow
5 years 5 months ago
Zoomatology – Present in Absentia
Unknowingly, you have become a zoomatologist – an old dog who has mastered the new trick. Despite the shutdowns and lockdowns, you can be everywhere, do everything, and learn by being present in absentia.
https://t.co/8iAV5gvkkt https://t.co/zEYvnVuari
Long-term outcomes of kids with childhood-onset systemic lupus erythematosus (cSLE) are uncommon, but this cSLE cohort analysis suggests that SLE significantly impacts their future education, vocation, and employment as they reach adulthood.
JAMA has posted an insights article reviewing autoimmune thyroid disease in women. Thyroid autoimmunity has a higher prevalence in women and with increasing age.
Similar to many autoimmune disorders, thyroid disease is more common in women than in men.
Fecal microbiota transplantation (FMT) showed disappointing results among patients with active psoriatic arthritis, a small randomized trial found.
Dr. John Cush RheumNow
5 years 5 months ago
New download available! Osteoarthritis vs. Rheumatoid Arthritis
https://t.co/qvVEcKqNAM https://t.co/3f8sRSgyQo
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: Higher Cardiovascular Risks with Systemic Lupus Erythematosus
The Journal of the American College of Cardiology has published a study showing that patients with SLE have an increased risk of HF and other long-term cardiovascular outcomes.
https://t.co/g07tIP5jBx https://t.co/3fHzgrJjUi
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: Uric Acid: A Major Player in the Metabolic Syndrome
Uric acid, and hyperuricemia, has been closely linked with may of the components of the metabolic syndrome, which is largely a consequence of excessive fat storage.
https://t.co/ObQ0LURodb https://t.co/HT35ODnFkn
Dr. John Cush RheumNow
5 years 5 months ago
Risk factors for Kawasaki disease in Taiwan compared 4197 KD pts to controls. KD was more common in Males (OR 1.47), older mothers (>35 y; OR, 1.18), and in multivariable analysis, maternal ankylosing spondylitis (OR 2.02). https://t.co/4qbddaYkqY
Dr. John Cush RheumNow
5 years 5 months ago
Real world comparision of baricitinib (n 138) and tofacitinib (n 156) in #RA patients shows at wk 24, BARI out performed TOFA - CDAI remission (40.4 vs 28.3%) and CDAI LDA (81.6 vs 69.3%); safety signals were equal between groups. https://t.co/0quNNGB18K
